Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

30 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Phosphoprotein patterns predict trametinib responsiveness and optimal trametinib sensitisation strategies in melanoma.
Rožanc J, Sakellaropoulos T, Antoranz A, Guttà C, Podder B, Vetma V, Rufo N, Agostinis P, Pliaka V, Sauter T, Kulms D, Rehm M, Alexopoulos LG. Rožanc J, et al. Among authors: sakellaropoulos t. Cell Death Differ. 2019 Aug;26(8):1365-1378. doi: 10.1038/s41418-018-0210-8. Epub 2018 Oct 15. Cell Death Differ. 2019. PMID: 30323272 Free PMC article.
Mechanism-based biomarker discovery.
Antoranz A, Sakellaropoulos T, Saez-Rodriguez J, Alexopoulos LG. Antoranz A, et al. Among authors: sakellaropoulos t. Drug Discov Today. 2017 Aug;22(8):1209-1215. doi: 10.1016/j.drudis.2017.04.013. Epub 2017 Apr 27. Drug Discov Today. 2017. PMID: 28458042 Review.
Network-based technologies for early drug discovery.
Fotis C, Antoranz A, Hatziavramidis D, Sakellaropoulos T, Alexopoulos LG. Fotis C, et al. Among authors: sakellaropoulos t. Drug Discov Today. 2018 Mar;23(3):626-635. doi: 10.1016/j.drudis.2017.12.001. Epub 2017 Dec 30. Drug Discov Today. 2018. PMID: 29294361 Review.
Selective cytotoxicity of the herbal substance acteoside against tumor cells and its mechanistic insights.
Cheimonidi C, Samara P, Polychronopoulos P, Tsakiri EN, Nikou T, Myrianthopoulos V, Sakellaropoulos T, Zoumpourlis V, Mikros E, Papassideri I, Argyropoulou A, Halabalaki M, Alexopoulos LG, Skaltsounis AL, Tsitsilonis OE, Aligiannis NN, Trougakos IP. Cheimonidi C, et al. Among authors: sakellaropoulos t. Redox Biol. 2018 Jun;16:169-178. doi: 10.1016/j.redox.2018.02.015. Epub 2018 Mar 1. Redox Biol. 2018. PMID: 29505920 Free PMC article.
Non-lethal proteasome inhibition activates pro-tumorigenic pathways in multiple myeloma cells.
Skorda A, Sklirou AD, Sakellaropoulos T, Gianniou DD, Kastritis E, Terpos E, Tsitsilonis OE, Florea BI, Overkleeft HS, Dimopoulos MA, Alexopoulos LG, Trougakos IP. Skorda A, et al. Among authors: sakellaropoulos t. J Cell Mol Med. 2019 Dec;23(12):8010-8018. doi: 10.1111/jcmm.14653. Epub 2019 Sep 30. J Cell Mol Med. 2019. PMID: 31568628 Free PMC article.
Prediction of combination therapies based on topological modeling of the immune signaling network in multiple sclerosis.
Bernardo-Faura M, Rinas M, Wirbel J, Pertsovskaya I, Pliaka V, Messinis DE, Vila G, Sakellaropoulos T, Faigle W, Stridh P, Behrens JR, Olsson T, Martin R, Paul F, Alexopoulos LG, Villoslada P, Saez-Rodriguez J. Bernardo-Faura M, et al. Among authors: sakellaropoulos t. Genome Med. 2021 Jul 16;13(1):117. doi: 10.1186/s13073-021-00925-8. Genome Med. 2021. PMID: 34271980 Free PMC article.
30 results